Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases (IRDs) and other retinal and refractive disorders. It focuses on genetic medicine aimed at preserving and restoring vision for patients with rare eye conditions.
2 investors
Oral Genome offers a saliva-based, point-of-care testing platform that uses a smartphone app to analyze a test card and identify oral and whole-body health risk indicators within minutes. It is designed for dental, medical, institutional, and individual use across clinical, public-health, and community settings.
2 investors
2 investors
OrdaΕs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.
2 investors
Organicin Scientific develops the CinThesis platform for applications in animal health and aquaculture sectors. The company focuses on translating its technology into products for these life science-related markets.
2 investors
Origin generates spatial molecular maps from patient tumor samples to enable cancer biology research in native tissue context. The platform combines spatial transcriptomics, imaging, and functional perturbation assays on fresh and archived tumors, paired with AI models for drug response prediction and target discovery.
2 investors
Orikine Bio develops engineered cytokines called Foldikinesβ’ to reprogram immune responses for treating autoimmune and inflammatory diseases. The platform uses bi-specific cytokines designed to target specific immune cells with precision while minimizing off-target toxicities.
2 investors
OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.
2 investors
2 investors
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.
2 investors
Unable to determine from the page provided. The team page contains only a biographical entry for a pain management physician without company background or product information.
2 investors
Ottimo Pharma is a clinical-stage biotech company developing PD-1/VEGFR2 dual-paratopic antibodies for cancer treatment. Its lead candidate, OTP-01, is being tested in a Phase I/IIA study across oncology centers in the US and Australia.
2 investors
Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases. Its lead programme targets an E3 ligase in hard-to-treat solid tumours.
2 investors
Ovation provides access to genomic data linked to clinical information at scale to support drug discovery and precision medicine development. The company offers a cloud-based laboratory information management system and a research network that connects clinical laboratories to enable molecular test adoption and biobanking of samples for research.
2 investors
Ovid Therapeutics develops medicines for children and adults with epilepsies and brain conditions, focusing on anti-seizure and neurological treatments. The company is led by a team with decades of combined experience in biotech and pharmaceutical development, having supported the launch of more than 25 new medicines.
2 investors
Owlo develops patented optical imaging technology that enables non-invasive, real-time 3D imaging deep within biological tissue. The company targets applications in IVF, drug discovery, and ophthalmology.
2 investors
Owlstone Medical develops a breath-based diagnostic platform for non-invasive disease detection across respiratory conditions, cancers, and digestive health. The company serves academic, clinical, and pharmaceutical research partners seeking to develop breath biomarker applications for precision medicine and early diagnosis.
2 investors
Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions. The company provides manufacturing, development, and technical services to clients developing advanced therapies.
2 investors
Oxford Brain Diagnostics provides CDM Insights, a clinical software platform that analyzes MRI scans to detect and monitor microstructural changes in the brain for early diagnosis of neurodegenerative conditions. The platform integrates with standard hospital MRI systems and delivers quantitative brain assessment reports to clinicians within 12 hours.
2 investors
Oxford Science Enterprises is a venture-building investment firm, working in partnership with the University of Oxford, that funds and creates companies based on scientific research from Oxford, Harwell and Culham. It provides capital and company-building support to spin ventures out of academic breakthroughs across deep science fields.
2 investors
A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments. Its offerings reference products such as a once-weekly combined hormonal contraceptive patch.
2 investors
Pacific Biosciences develops long-read DNA and RNA sequencing platforms and kits for genomics research, including whole genome, targeted, epigenetic, and RNA sequencing applications. The company serves research institutions, clinical laboratories, and diagnostic organizations in genomics and life sciences.
2 investors
Pacifico produces mycelium-based "Mycomeat" sold under the Viando brand, offering poultry alternatives (with pork and fish planned) grown in steel fermentation bioreactors. It supplies clean-label meat alternatives to B2B food manufacturers and food service chains that integrate into existing meat supply chains and recipes.
2 investors
PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
2 investors